Inscriere cercetatori

Daca aveti cont Ad Astra si de Facebook, intrati pe pagina de profil pentru a da dreptul sa va logati pe site doar cu acest buton.

Site nou !

Daca nu va puteti recupera parola (sau aveti alte probleme), scrieti-ne la pagina de contact. Situl vechi se gaseste la adresa


Platelet microparticles: a potential predictive factor of overall survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy

Domenii publicaţii > Ştiinţe medicale + Tipuri publicaţii > Articol în revistã ştiinţificã

Autori: Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S.

Editorial: Elsevier, Eur Urol, 2008 June 20 [Epub ahead of print), 55(4), 2009.


Background: Several studies suggest a causal relationship between platelet activation and cancer metastasis. Activated platelet microparticles (PMPs) release vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which play a major role in angiogenesis.
Objective: We conducted a prospective, nonrandomised, single-centre study in hormone-refractory prostate cancer (HRPC) patients to determine the impact of PMPs on the outcome.
Design, setting, and participants: Eligible chemonaive and metastatic HRPC patients received docetaxel-based chemotherapy and a low dose of prednisone.
Intervention: PMPs in whole blood were quantified before the start of chemotherapy through flow cytometry using an anti-CD41a monoclonal antibody, and plasma VEGF and bFGF were determined with an enzyme-linked immunosorbent assay.
Measurements: The primary end point was to evaluate the impact of the PMPs on overall survival (OS). We also studied the statistical interaction between PMPs and platelets and their relationship with OS. The median PMP value was used to sort patients into two groups.
Results and limitations: Data of 43 consecutive HRPC patients treated in a single French centre were analysed. Significant correlations were observed among performance status (PS), platelets, and PMP level for the Eastern Cooperative Oncology Group (ECOG). The median OS was significantly shorter for patients with >6867 PMPs per μl of whole blood than for those with lower values (16.7 vs 26.4 mo, p=0.013). A significant relationship was found between OS and PMPs, whereas a statistical interaction term between PMPs and platelets was significantly associated with OS (p=0.019). No association was found between OS and plasma VEGF and bFGF. In the multivariate analysis, only baseline prostate-specific antigen (PSA) and ECOG PS remained significantly predictive of risk of death.
Conclusions: In HRPC patients, PMPs and their interaction with platelets were predictive of outcome. A biologic association between PMPs and the OS of HRPC patients, independent of chemotherapy regimen, should be demonstrated by confirmatory prospective studies.

Cuvinte cheie: cancer de prostata, supravietuire globala, microparticule plachetare // prostate cancer, survival, platelet-microparticles